Teacher Retirement System of Texas boosted its position in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 31.1% during the second quarter, Holdings Channel reports. The fund owned 5,444 shares of the biopharmaceutical company’s stock after buying an additional 1,291 shares during the period. Teacher Retirement System of Texas’ holdings in Alnylam Pharmaceuticals were worth $302,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Slate Path Capital LP boosted its stake in shares of Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock worth $71,244,000 after buying an additional 410,000 shares during the period. State Street Corp boosted its stake in shares of Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock worth $121,553,000 after buying an additional 262,783 shares during the period. Bridger Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $50,041,000. Schroder Investment Management Group boosted its stake in shares of Alnylam Pharmaceuticals by 235.0% in the second quarter. Schroder Investment Management Group now owns 18,592 shares of the biopharmaceutical company’s stock worth $1,032,000 after buying an additional 13,042 shares during the period. Finally, Turner Investments L.P. bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $575,000. Institutional investors and hedge funds own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) opened at 35.32 on Friday. The firm’s market cap is $3.03 billion. Alnylam Pharmaceuticals Inc. has a 1-year low of $33.16 and a 1-year high of $110.75. The firm has a 50-day moving average price of $65.33 and a 200 day moving average price of $65.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The company had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same quarter last year, the company posted ($0.85) EPS. The company’s revenue for the quarter was up .2% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals Inc. will post ($4.68) earnings per share for the current year.
A number of analysts have weighed in on the company. Leerink Swann reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 19th. Jefferies Group lowered their price target on Alnylam Pharmaceuticals from $86.00 to $58.00 and set a “buy” rating on the stock in a research report on Thursday, October 6th. Needham & Company LLC reiterated a “buy” rating and issued a $152.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, July 25th. JPMorgan Chase & Co. upped their price target on Alnylam Pharmaceuticals from $80.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, August 5th. Finally, Stifel Nicolaus lowered their price target on Alnylam Pharmaceuticals from $68.00 to $36.00 and set a “hold” rating on the stock in a research report on Thursday, October 6th. Eight investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $79.50.
In other news, CEO John Maraganore sold 30,151 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total value of $1,950,468.19. Following the transaction, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David E. I. Pyott acquired 27,900 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 13th. The shares were purchased at an average price of $37.00 per share, for a total transaction of $1,032,300.00. The disclosure for this purchase can be found here. 4.00% of the stock is owned by insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.